You are here: Industry Insights > Immunogen

News List

ImmunoGen gets FDA breakthrough therapy status for IMGN632 to treat relapsed or refractory BPDCN pharmaceutical-business-review
October 10, 2020
ImmunoGen has secured breakthrough therapy status from the US Food and Drug Administration (FDA) for its IMGN632 to treat patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN).
ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial pharmafile
May 17, 2019
Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 trial of its ovarian cancer drug mirvetuximab soravtansine.
ImmunoGen's antibody-drug conjugate mirvetuximab soravtansine misses main goal of Phase III ovarian cancer study firstwordpharma
March 03, 2019
ImmunoGen announced Friday that a Phase III study of the experimental antibody-drug conjugate (ADC) mirvetuximab soravtansine in patients with folate receptor (FR) alpha-positive, platinum-resistant ovarian cancer failed to meet its primary endpoint of pr
ImmunoGen Announces Sale of Residual Kadcyla Royalties firstwordpharma
January 09, 2019
MTS Health Partners, L.P. acted as exclusive financial advisor to ImmunoGen and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as special transactional counsel to ImmunoGen.
ImmunoGen Announces Sale of Residual Kadcyla Royalties firstwordpharma
January 09, 2019
MTS Health Partners, L.P. acted as exclusive financial advisor to ImmunoGen and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as special transactional counsel to ImmunoGen.
New business chief at ImmunoGen biospectrumasia
April 27, 2018
ImmunoGen appoints Blaine McKee, Ph.D. as EVP and Chief Business Officer.
ImmunoGen Stock Climbs on Positive Ovarian Cancer Data biospace
March 27, 2018
ImmunoGen has published positive efficacy and tolerability data for its mirwuxuxima soravtansine combined with Merck's Keytruda in the FORWARD II trial in platinum-resistant epithelial ovarian cancer (EOC).
ImmunoGen and Jazz collaborate to develop and market ADC products pharmaceutical-technology
August 31, 2017
ImmunoGen has entered a collaboration and option agreement to grant exclusive worldwide rights to Jazz Pharmaceuticals for the development and commercialisation of two haematology-related antibody-drug conjugate (ADC) candidates, IMGN779 and IMGN632.